Visualizing Health Policy: Recent Trends in Prescription Drug Costs
This Visualizing Health Policy infographic with JAMA spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices.
View the Latest: Prices
Filter
-
-
Visualizing Health Policy: Recent Trends in Prescription Drug Costs
News ReleaseThis Visualizing Health Policy infographic spotlights national spending on prescription drugs and the public’s views on pharmaceutical prices. Prescription drug spending rose sharply in 2014, driven by growth in expenditures on specialty drugs, including medications to treat cancer and hepatitis C.
-
Prescription Drug Rebates, Explained
VideoThis animation explains how rebates for prescription drugs work and why they matter in the debate about lowering drug costs. The video breaks down how prescription drug rebates are determined, who benefits from them, how they affect spending by insurers and consumers and the role of pharmacy benefit managers in the process.
-
Explainer Video Breaks Down Prescription Drug Rebates and Why They Matter in the Debate About Prescription Drug Costs
News ReleaseA new KFF animation explains how rebates for prescription drugs work, including how they are determined, who benefits from them, how they affect spending by insurers and consumers and the role of pharmacy benefit managers in the process.
-
Pricing and Payment for Medicaid Prescription Drugs
Issue BriefAttention to high list prices continues at both the state and federal levels with a number of policy proposals aimed at lowering drug prices and there is renewed interest in drug prices and reimbursement within Medicaid. Changes made in 2016 to federal rules governing how state Medicaid programs pay for drugs aimed to make the prices paid more accurate, but increased reliance on pharmacy benefit managers (PBMs) pose challenges to drug price transparency. This brief explains Medicaid prescription drug prices to help policymakers and others understand Medicaid’s role in drug pricing and any potential consequences of policy changes for the program.
-
Few Consumers Use Information on Health Provider Quality or Price
From Drew AltmanIn this column for The Wall Street Journal's Think Tank, Drew Altman discusses new poll findings showing very small numbers of consumers are using provider quality and price information.
-
Americans’ Health Priorities Diverge From Washington’s Focus on Obamacare
News ReleaseIn his latest column for The Wall Street Journal's Think Tank, Drew Altman finds the public’s health-care priorities have more to do with drug costs and other real-world issues people deal with using the health-care system than the ongoing partisan wrangling over the Affordable Care Act. All previous columns by Drew Altman are available online.
-
High Health-Care Prices: More Talk Than Action
From Drew AltmanIn this column for The Wall Street Journal's Think Tank, Drew Altman explores how price is the major factor that distinguishes the cost of our health care system from those in other developed nations, yet most efforts in the U.S. to address health-care costs don’t focus on price much at all.
-
High Health-Care Prices: More Talk Than Action
News ReleaseIn his latest column for The Wall Street Journal's Think Tank, Drew Altman explores how price is the major factor that distinguishes the cost of our health care system from those in other developed nations, yet most efforts in the U.S. to address health-care costs don't focus on price much at all.
-
Health Spending Is Rising More Sharply Again
From Drew AltmanIn this column for The Wall Street Journal's Think Tank, Drew Altman discusses why high health care prices are a problem for consumers but not a cause of renewed growth in health spending.